



## Autolus Therapeutics PLC 2026 Annual General Meeting Results

On June 29, 2026, Autolus Therapeutics PLC (the “Company”) held its 2026 annual general meeting of shareholders (the “AGM”).

At the AGM, the holders of 168,805,042 votes of the Company’s ordinary shares, which may be represented by American Depositary Shares (“ADSs”), were represented in person or by proxy, constituting a quorum.

Voting at the AGM was conducted by way of a poll, and each ordinary share, which may be represented by ADSs, issued and outstanding as of the close of business on the record date was entitled to one (1) vote on each resolution at the AGM.

The following are the voting results for the proposals considered and voted upon at the AGM, each of which was an ordinary resolution requiring a simple majority:

Proposal	For	Against	Vote Withheld
Resolution 1: To receive and adopt the Company’s accounts for the financial year ended 31 December 2025 and the associated reports of the Directors and auditors (the “2025 Annual Report and Accounts”).	165,846,326	2,895,344	75,901
Resolution 2: To approve the Directors’ remuneration report (excluding the Directors’ remuneration policy set out on pages 41 to 54 of the Directors’ remuneration report), which is set out on pages 38 to 67 of the 2025 Annual Report and Accounts.	156,192,216	12,502,946	122,409
Resolution 3: To appoint Ernst & Young LLP (US) as auditors of the Company to hold office from the conclusion of the 2026 AGM until the conclusion of the 2027 AGM and to authorise the Directors to determine the auditors’ remuneration.	165,871,368	2,872,225	73,978
Resolution 4: To re-elect Mr. M Bonney as a Director.	165,491,394	3,312,126	14,051
Resolution 5: To re-elect Dr. E Leiderman as a Director.	165,741,204	3,063,838	12,529

<b>Proposal</b>	<b>For</b>	<b>Against</b>	<b>Vote Withheld</b>
Resolution 6: To re-elect Mr. R.W. Azelby as a Director.	162,133,091	6,671,776	12,704

Based on the foregoing votes, the shareholders approved all of the proposals. The results were in line with the recommendations made by the Company's board of directors.